VanEck Morningstar US Wide Moat UCITS ETF A

The Product´s investment objective is to track, before fees and expenses, the price and yield performance of the Morningstar Wide Moat Focus IndexTM(the "Index"). In order to seek to achieve its investment objective, the Manager will normally use a replication strategy by investing directly in the underlying equity securities of the Index being the equity stocks, American depository receipts (ADRs), and global depository receipts (GDRs) that consists of the component securities of the Index. The Product may also (or alternatively) invest in financial derivative instruments (FDIs) which relate to the Index or constituents of the Index. The FDIs which the Product may use are futures, options (puts and calls), swaps (including equity swaps and swaps on the Index), currency forwards and non-deliverable forwards (a forward contract that does not require settlement on maturity) (NDFs). The Product may also invest in ancillary liquid assets and money market instruments which may include bank deposits, depositary receipts, certificates of deposit, fixed or floating rate instruments (treasury bills), commercial paper, floating rate notes and freely transferable promissory notes. The ancillary liquid assets, money market instruments and FDI (other than permitted unlisted investments) will be listed or traded on the Markets referred to in Appendix II of the Prospectus. Where it is not practical or cost efficient for the Fund to fully replicate the Index, the Manager may utilise an optimised sampling methodology. The Product invests in the underlying (physical) securities that make up the Index and does not take part in securities lending. The Product may not invest more than 10% of its Net Asset Value in open-ended collective investment schemes. Furthermore, the Product may not invest less than 51% of its Net Asset Value in equity securities which constitute "equity participation" within the meaning of section 2, Article 8 of the German Investment Tax Act. The Product, using

Physical replication

PIR compliant

No

PEA compliant

No

PEA-PME compliant

No